Radboud University Nijmegen Medical Centre and TcLand Expression work together on research into effectiveness of rheumatism drugs

Rheumatoid Arthritis

Radboud University Nijmegen Medical Centre (RUNMC) and the French company TcLand Expression are set to join forces in research into predicting the effectiveness of drugs for rheumatoid arthritis. This joint research will focus on biomarkers in patients with rheumatism, and will result in a faster and clearer indication of whether drugs are likely to work for specific groups of patients.  

The collaboration between RUNMC and TcLand is beneficial to both parties. The various phases in the translational research chain (turning fundamental knowledge from the labs into validated drugs for patients) will run more effectively and smoothly. The partnership with TcLand Expression is a good example of valorisation for RUNMC: developing knowledge, applying it to society and generating economic activity in partnership with the business sector.

"This research is perfectly suited to our aim of developing more effective treatment methods. We are pleased to be working alongside TcLand in their efforts to develop the first companion diagnostic test for rheumatoid arthritis", said Prof. Piet van Riel, head of the Rheumatology department at RUNMC. "This is another clear example that demonstrates how the right combination of multiple internationally-renowned teams, in this case Anthropogenetics and Rheumatology, makes RUNMC an attractive partner for pioneering research", Prof. Han Brunner, head of the Human Genetics department continues.

"TcLand has developed a test predictive of response to Infliximab therapy in Rheumatoid Arthritis. We are pleased to collaborate with Prof. Piet van Riel and Prof. Han Brunner and their teams on researching the whole class of anti-TNFs. We are hopeful to bring a product to the market that will better patient's lives by guiding them more effectively to the right treatment", emphasized Alessandra Cervino, VP R&D and Biostatistics, TcLand Expression. 

Personalized medicine, a current heatlh issue

The healthcare system is showing a definite trend towards developing personalized medicine. RUNMC has been monitoring the effects of treatment methods in rheumatism patients for many years; the DREAM initiative is one such project. The aim is to arrive at more effective treatment, which will enable doctors to prescribe patients with rheumatism the right drugs at the earliest possible stage. This will bring the disease under control more swiftly, thereby saving costs and putting less strain on the body. The use of companion diagnostics will play an increasingly important part in new treatment methods. These developments will in turn represent an important step forward in the development of personalized medicine in the field of rheumatism.


<< back to overview news items